Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 1/2007

01-03-2007 | Clinical Trial

Monitoring primary breast cancer throughout chemotherapy using FDG-PET

Authors: Garry M. McDermott, Andrew Welch, Roger T. Staff, Fiona J. Gilbert, Lutz Schweiger, Scott I. K. Semple, Tim A. D. Smith, Andrew W. Hutcheon, Iain D. Miller, Ian C. Smith, Steven D. Heys

Published in: Breast Cancer Research and Treatment | Issue 1/2007

Login to get access
Metadata
Title
Monitoring primary breast cancer throughout chemotherapy using FDG-PET
Authors
Garry M. McDermott
Andrew Welch
Roger T. Staff
Fiona J. Gilbert
Lutz Schweiger
Scott I. K. Semple
Tim A. D. Smith
Andrew W. Hutcheon
Iain D. Miller
Ian C. Smith
Steven D. Heys
Publication date
01-03-2007
Published in
Breast Cancer Research and Treatment / Issue 1/2007
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-006-9316-7

Other articles of this Issue 1/2007

Breast Cancer Research and Treatment 1/2007 Go to the issue

Letter to the Editor

Do nipple aspirate fluid epithelial cells and their morphology predict breast cancer development?

Clinical Trial

The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers

Epidemiology

Variants in estrogen metabolism and biosynthesis genes and urinary estrogen metabolites in women with a family history of breast cancer

Preclinical study

Prostate-derived Ets transcription factor (PDEF) downregulates survivin expression and inhibits breast cancer cell growth in vitro and xenograft tumor formation in vivo

Clinical Trial

The decision-making experience among women diagnosed with stage I and II breast cancer

Epidemiology

A deletion in CHEK2 of 5,395 bp predisposes to breast cancer in Poland
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits